Genmab A/S
Denmark
436 articles about Genmab A/S
-
BioNTech and Genmab Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates
8/5/2022
BioNTech SE and Genmab A/S announced an expansion of their global strategic collaboration to develop and commercialize novel immunotherapies for the treatment of cancer patients.
-
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2022
7/19/2022
COPENHAGEN, Denmark; July 19, 2022 – Genmab A/S announced that worldwide net trade sales of DARZALEX®,including sales of the subcutaneous formulation,as reported by Johnson & Johnson were USD 1,986 million in the second quarter of 2022.
-
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
7/18/2022
Genmab A/S announced that AbbVie will submit a conditional marketing authorization application with the European Medicines Agency for subcutaneous epcoritamab, an investigational bispecific antibody, for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma, in the second half of 2022.
-
Genmab to Submit Biologics License Application to U.S. Food and Drug Administration for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
6/30/2022
Genmab A/S (Nasdaq: GMAB) today announced its intent to submit a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for subcutaneous epcoritamab (DuoBody®-CD3xCD20), an investigational bispecific antibody, for the treatment of patients with relapsed/refractory large B-cell lymphoma (LBCL), in the second half of 2022.
-
Genmab A/S: Major Shareholder Announcement
6/20/2022
Genmab A/S announces under reference to Section 30 of the Danish Capital Markets Act that Wellington Management Group LLP has informed us that, as of June 15, 2022 Wellington Management Group LLP had decreased their holding of shares in Genmab A/S to4.99% of the share capital and voting rights in Genmab A/S, so that through shares and financial instruments they held the voting rights to 3,293,871 shares in Genmab A/S, which amounts to 5.00% of the share capital and voting rights in Genmab A/S.
-
Genmab and AbbVie announce positive data in large b-cell lymphoma, Intra-Cellular's bipolar depression candidate hits the endpoint in Phase III and more.
-
Genmab's Phase II expansion cohort of the EPCORE NHL-1 clinical trial revealed that its investigational bispecific antibody epcoritamab induced a durable response in patients with LBCL.
-
Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium
6/11/2022
Genmab A/S announced primary results from the large B-cell lymphoma expansion cohort in the EPCORE™ NHL-1 phase 2 clinical trial evaluating subcutaneous epcoritamab, an investigational bispecific antibody.
-
Genmab A/S is seeking a new arbitration ruling against Janssen seeking $405 million-plus interest in accrued milestone payments for Darzalex Faspro.
-
Genmab Commences New Arbitration Under License Agreement With Janssen
6/9/2022
Genmab A/S (Nasdaq:GMAB) announced today that it has commenced a new arbitration under its license agreement with Janssen Biotech, Inc. (Janssen) for daratumumab.
-
More oncology firms presented positive developments in their respective cancer research programs at the 2022 ASCO annual meeting this week.
-
Seagen and Genmab Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
6/6/2022
Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced interim data from the innovaTV 205 trial, which included data evaluating tisotumab vedotin (TIVDAK®) in combination with pembrolizumab (Cohort E) in patients with recurrent or metastatic cervical cancer.
-
Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
6/6/2022
Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) today announced interim data from the innovaTV 205 trial, which included data evaluating tisotumab vedotin (TIVDAK®) in combination with pembrolizumab (Cohort E) in patients with recurrent or metastatic cervical cancer.
-
Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
5/26/2022
Genmab A/S announced that multiple abstracts evaluating several investigational medicines in the company’s pipeline, or created using Genmab’s innovative drug development platforms, will be presented at the 2022 American Society of Clinical Oncology Annual Meeting, being held at McCormick Place, in Chicago, IL, and virtually, June 3-7.
-
Genmab Announces Multiple Abstracts to Be Presented at the European Hematology Association (EHA) Annual Congress
5/12/2022
Genmab A/S announced that multiple abstracts evaluating epcoritamab, an investigational subcutaneous bispecific antibody, will be presented at the European Hematology Association Annual Congress, being held in Vienna, Austria, and virtually, June 9-12.
-
Genmab Announces Financial Results for the First Quarter of 2022
5/11/2022
Genmab Announces Financial Results for the First Quarter of 2022.
-
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2022
4/19/2022
Genmab A/S announced that worldwide net trade sales of DARZALEX®,including sales of the subcutaneous formulation,as reported by Johnson & Johnson were USD1,856million in the first quarter of 2022.
-
AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
4/13/2022
AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) today announced topline results from the first cohort of the EPCORE™ NHL-1 phase 1/2 clinical trial evaluating epcoritamab (DuoBody®-CD3xCD20), an investigational subcutaneous bispecific antibody.
-
Genmab Announces the Initial Resolution of its Arbitration with Janssen Relating to their Daratumumab License Agreement
4/7/2022
Genmab A/S (Nasdaq: GMAB) announced today an award in the binding arbitration of two matters arising under its license agreement with Janssen Biotech, Inc. (Janssen) relating to daratumumab.
-
Genmab Announces U.S. Food and Drug Administration Granted Orphan-Drug Designation to Epcoritamab (DuoBody®-CD3xCD20) in Follicular Lymphoma
3/8/2022
Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to the investigational medicine, epcoritamab (DuoBody®-CD3xCD20), for the treatment of follicular lymphoma (FL).